Abstract: Circulating Endothelial Cells are isolated from patient blood and gene expression of the cells is analyzed to assess a medical condition or the tissue of origin of the cell. Kits for conducting the method are also provided.

Abstract: A remote node for a wavelength-division-multiplexed passive optical network (WDM PON). The remote node comprises means for receiving uplink optical signals from one or more optical network units of the WDM PON; a broadband reflector for reflecting a self-seeding portion of the respective uplink optical signals to the respective uplink light sources; and wherein the reflector comprises a gain medium and is configured for receiving a pump optical signal from a central office of the WDM PON for amplifying the self seeding portion of the respective uplink optical signal.

Abstract: Circulating Endothelial Cells are isolated from patient blood and gene expression of the cells is analyzed to assess a medical condition or the tissue of origin of the cell. Kits for conducting the method are also provided.

Abstract: A method of providing a prognosis of breast cancer is conducted by analyzing the expression of a group of genes. Gene expression profiles in a variety of medium such as microarrays are included as are kits that contain them.

Abstract: Methods are disclosed for the identification of gene sets that are differentially expressed in PBMCs of patients diagnosed with a pre-diabetic disease state and overt type II diabetes. 3 gene and 10 gene signatures are shown to accurately predict a diabetic disease state in a patient. The application also described kits for the rapid diagnosis of diabetic disease states in patients at a point of care facility.

Abstract: A remote node for a wavelength-division-multiplexed passive optical network (WDM PON). The remote node comprises means for receiving uplink optical signals from one or more optical network units of the WDM PON; a broadband reflector for reflecting a self-seeding portion of the respective uplink optical signals to the respective uplink light sources; and wherein the reflector comprises a gain medium and is configured for receiving a pump optical signal from a central office of the WDM PON for amplifying the self seeding portion of the respective uplink optical signal.

Abstract: A wavelength-division-multiplexed passive optical network (WDM PON) comprising: a remote node (RN) comprising a light source for generating a seeding signal; and one or more optical network units (ONUs), each ONU comprising a laser source configured for receiving a portion of the seeding light signal from the RN.

Abstract: A method for predicting with high specificity from RTPCR detected markers if a patent is likely to respond to docetaxel treatment is disclosed. RTPCR detects the presence of absence of certain mutations due to fusion events. Together, with other protein markers, additional stratification is possible to identify patents suited for docetaxel therapy as opposed to for alternative treatments.

Abstract: We analyzed bone marrow from 67 patients from a phase 2 study of farnesyltransferase inhibition with tipifarnib (R115777, ZARNESTRA®), in older adults with previously untreated, poor-risk acute myeloid leukemia (AML) for N-Ras mutations, global gene expression, and/or quantitative PCR (qPCR) of specific genes. Microarray profiling identified a two-gene expression ratio (RASGRP1:APTX) which provided the greatest accuracy for predicting response to tipifarnib. We demonstrated that this classifier could predict response to tipifarnib in an independent set of 54 samples from relapsed or refractory AML, with a NPV and PPV of 92% and 28%, respectively (odds ratio of 4.4). Therefore, in both newly diagnosed and relapsed or refractory AML, this classifier improves the overall response rate by approximately 50% while maintaining a high NPV, and significantly improves patient overall survival.

Abstract: An assay for identifying early stage malignant melanocyte in biopsy tissues is provided by determining whether differential expression of a particular gene indicative of melanoma exceed a cut-off value.

Abstract: An assay for diagnosing or prognosticating prostate cancer incorporates the detection of hypermethylation of SEQ ID NO 1, SEQ ID NO 3, and SEQ ID NO 2 genes and may be incorporated into a nomogram.

Abstract: The present invention provides a method of identifying origin of a metastasis of unknown origin by obtaining a sample containing metastatic cells; measuring Biomarkers associated with at least two different carcinomas; combining the data from the Biomarkers into a linear discrimination analysis where the linear discrimination analysis normalizes the Biomarkers against a reference; and imposes a cut-off which optimizes sensitivity and specificity of each Biomarker, weights the prevalence of the carcinomas and selects a tissue of origin determining origin based on highest probability determined by the linear discrimination analysis or determining that the carcinoma is not derived from a particular set of carcinomas; and optionally measuring Biomarkers specific for one or more additional different carcinoma, and repeating the steps for additional Biomarkers.

Abstract: A method of providing a prognosis of breast cancer is conducted by analyzing the expression of a group of genes. Gene expression profiles in a variety of medium such as microarrays are included as are kits that contain them.

Abstract: A method of diagnosing cancer by identifying differential modulation of each gene (relative to the expression of the same genes in a normal population) in a combination of genes selected from two groups of genes. Gene expression portfolios and kits for employing the method are further aspects of the invention.

Abstract: Kits and articles include reagents for conducting a seven gene assay to stage colon cancer as Stage II or Stage III colon cancer.

Abstract: Disclosed in this specification is a method of defining chromosome regions of prognostic value by summarizing the significance of all SNPs (single nucleotide polymorphism) in a predetermined section of a chromosome to define chromosome regions of prognostic value. Based on the SNPs in specified genes, a more accurate prognosis for breast cancer may be provided.

Abstract: A method of prognosticating metastasis in a breast cancer patient involves identifying differential modulation of each gene (relative to the expression of the same genes in a normal population) in a combination of genes as well as kits for employing the method.

Abstract: About 70% to 80% of breast cancers express estrogen receptor-? (ER?), and estrogens play important roles in the development and growth of hormone-dependent tumors. Together with lymph node metastasis, tumor size and histological grade, ER status is considered one of the prognostic factors in breast cancer, and an indicator for hormonal treatment. 147 genes and 112 genes with significant P-value and having significant differential expression between ER+ and ER? tumors were identified from the LCM data set and bulk tissue data set, respectively. 61 genes were found to be common in both data sets, while 85 genes were unique to the LCM data set and 51 genes were present only in the bulk tumor data set. Pathway analysis with the 85 genes using Gene Ontology suggested that genes involved in endocytosis, ceramide generation, Ras/ERK/Ark cascade, and JAT-STAT pathway may play roles related to ER.

Abstract: The present invention provides a method for predicting distant metastasis of lymph node negative primary breast cancer by obtaining breast cancer cells; isolating nucleic acid and/or protein from the cells; and analyzing the nucleic acid and/or protein to determine the presence, expression level or status of a Biomarker selected from the pathways in Table 2.

Abstract: A method of diagnosing cancer by identifying differential modulation of each gene (relative to the expression of the same genes in a normal population) in a combination of genes selected from two groups of genes. Gene expression portfolios and kits for employing the method are further aspects of the invention.